PNH Treatment Market Size Worth $5.8 Billion by 2025 | CAGR: 11.2%: Grand View Research, Inc.
SAN FRANCISCO, June 10, 2019 /PRNewswire/ -- The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 5.8 billion by 2025 at a 11.2% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Several factors such as rise in number of blood and bone marrow related disorders, increase in geriatric population, wider adoption of novel therapeutics, and emergence of biologics are driving the market.
https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg
Key suggestions from the report:
-- An estimated 5,000 - 6,000 people in U.S. suffer from PNH, with
approximately 450 new cases being reported annually
-- U.S. dominated the global PNH treatment market with more than 35% share
in 2017 due to high cost of treatment in U.S., potential approval of a
range of pipeline drugs, and adoption of novel therapeutics
-- Treatment with medication dominated the PNH market with a share of more
than 75% in 2017. Apart from drugs, the stem cell transplant segment is
projected to witness double-digit growth through the forecast period
-- Alexion, Akari, Apellis, Amgen, CinnaGen, Ra Pharmaceuticals, Alnylam,
Achillion, Novartis, Roche, and Regeneron Pharmaceuticals are some of
the key players in this market
-- Currently, 16 products are under clinical evaluation for PNH treatment
in various stages of development. Promising pipeline candidates such as
ALXN1210, Coversin, APL2, and RA101495 offer significant commercial
potential post regulatory approval.
Read 65 page research report with TOC on "Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), And Segment Forecasts, 2018 - 2025" at: https://www.grandviewresearch.com/industry-analysis/paroxysmal-nocturnal-hemoglobinuria-pnh-market
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder. It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe. The life-threatening disease often manifests in three forms: thrombosis, persistent intravascular hemolysis, and pancytopenia. Although information on its prevalence is scarce, PNH is estimated to affect more than 20,000 people worldwide with an incidence of about 1.3 per million annually and a prevalence of around 16 per million. PNH affects men and women equally. Although physical symptoms can begin at any age, they usually develop between 30-40 years of age.
Novel treatments including monoclonal antibodies, recombinant proteins, and cyclic peptides are gaining penetration in developed markets. However, high cost of therapy with Soliris and other emerging pipeline drugs presents a barrier in adoption in developing regions. Blood transfusion and supportive care are anticipated to lose momentum during the forecast period due to adverse side effects and sub-optimal efficacy.
Grand View Research has segmented the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market based on treatment and major markets:
-- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Outlook (Revenue,
USD Million; 2017 - 2025)
-- Medication
-- Stem Cell Transplant
-- Blood Transfusion
-- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Country Outlook
(Revenue, USD Million, 2017 - 2025)
-- U.S.
-- Japan
-- U.K.
-- Germany
-- France
-- Spain
-- Italy
Find more research reports on Pharmaceuticals Industry, by Grand View Research:
-- Anti-Osteoporosis Therapy And Fracture Healing Market - The driving
factors responsible for the growth of anti-osteoporosis therapy and
fracture healing market include increasing prevalence of osteoporosis in
aged women, rise in incidence of osteoporosis patients andgrowing
prevalence of bone diseases resulting out of changing lifestyle are some
factors fueling the market growth.
-- Aquaculture Therapeutics Market - The Culturing or farming of aquatic
animals like fishes, crustaceans, mollusks, algae, aquatic plants, and
the other aquatic organisms in different types of water is termed as
"Aquaculture"
-- Avian (Bird) Flu Treatment Market - Avian influenza (AI), can be
commonly known as bird flu. It is an infectious viral disease of birds.
It is generally found in ducks and geese which live in open rivers.
Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
View original content:http://www.prnewswire.com/news-releases/pnh-treatment-market-size-worth-5-8-billion-by-2025--cagr-11-2-grand-view-research-inc-300864338.html
SOURCE Grand View Research, Inc.
